Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial of PPP001 (Smokeable Marijuana) in Advanced Cancer Patients

Trial Profile

A Phase III Trial of PPP001 (Smokeable Marijuana) in Advanced Cancer Patients

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Marijuana (Primary)
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Tetra Bio Pharma
  • Most Recent Events

    • 05 Feb 2019 According to a Tetra Bio Pharma media release, the company has suspended the Phase III clinical program for PPP001 due to impurities found in the product. This suspension does not affect the timing of the European application. the company will take the next 6 months to assess the situation and propose a robust quality program to Health Canada.
    • 05 Feb 2019 Status changed from recruiting to suspended, according to a Tetra Bio Pharma media release.
    • 13 Jun 2018 According to a Tetra Bio Pharma media release, the company expects to complete this trial in Q4 of 2018 or Q1 of 2019 and will file for approval in Q1 of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top